alias25 schreef op 23 juli 2014 19:41:
Opzoek werk.
Er wordt veel gespiculeerd over de verdeelsleutel met Sobi.
Ik heb eens op internet gezocht. Men vindt geen duidelijke deals met Sobi en anderen pharmacseutische bedrijfen wat betreft de omzet verdeling.
De meeste spreken enkel over een milstone betaling.
1 enkele gevonden met winst verdeling over de omzet. Deze zal in de meeste gevallen in lijn liggen. Ik hanteer deze waarde voor Pharming 20 tot max 25%, vandaar dat Europa niet uit de grond schiet.
Voorbeeld:
ChondroCelect was the first cell-based product to be approved in Europe. It is currently available for patients and reimbursed in Belgium, the Netherlands and Spain. Sales of ChondroCelect in 2013 were Euro 4.3 million, a growth of 25% on a like-for-like basis over 2012.
Sobi will continue to market and distribute the product where it is currently available and has also acquired the exclusive rights to expand the product’s availability to patients in multiple additional territories, including the rest of the European Union, Norway, Switzerland, Turkey, and Russia, plus the countries of the Middle East and North Africa.
TiGenix will receive a royalty of 22% of the net sales of ChondroCelect in the first year of the agreement, and 20% of the net sales of ChondroCelect thereafter. There will be no upfront or milestone payments. The agreement will take effect on 1 June 2014, and has a duration of 10 years.